{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DCTH",
  "name": "Delcath Systems, Inc.",
  "url": "https://frontierpicks.com/dossiers/DCTH/",
  "json_url": "https://frontierpicks.com/dossiers/DCTH.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Post-print leg held and extended — 2026-08-21 close $17.14, 1.3% under the 52-week high of $17.36 — while the news line went quiet after the 2026-08-11 conference appearance. Nothing company-confirmed is dated until ESMO (2026-10-23) and the Q3 print (~2026-11-05, est.), so a self-funded 90%-gross-margin procedure ramp is now carried by flow at RSI(14) 74.1.",
  "invalidation_trigger": "A weekly close below $14.00 retraces the whole advance off the 2026-08-06 print (2026-08-21 close $17.14, RSI 74.1); secondary condition: FY26 revenue guided beneath the $104M floor, or active centers materially short of ~37 at the Q3 print (~2026-11-05, est.).",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "HEPZATO KIT was $27.1M of $29.133M Q2 2026 revenue; CHEMOSAT (Europe) is the $2.0M remainder — single-product concentration.",
    "Sell-side coverage is thin and dispersed: published post-print targets stand at $21 (BTIG, 2026-08-06) and $32 (HC Wainwright, 2026-08-07).",
    "Label-expansion readouts are late-decade: mCRC Phase 2 hepatic-PFS anticipated mid-2028, overall survival late-2028.",
    "Cash and investments $95.9M with no debt at 2026-06-30; two Phase 2 programs are funded from operations per the 2026-08-06 release.",
    "Short-interest figures differ by aggregator (2.69M shares / 7.80% of shares outstanding vs 2.184M / 6.38% of float); treat the precision loosely."
  ],
  "body_markdown": "## Current Thesis\nThe leg being bought is a liver-directed oncology procedure ramp that already funds itself. Q2 2026, reported 2026-08-06: revenue $29.133M against $26.259M consensus, diluted EPS $0.07 against a $(0.09) estimate, gross margin 90% versus 86% a year earlier, FY2026 guidance lifted to $104–108M against $103.242M consensus. Growth is a distribution variable — 31 active treatment centers at 2026-06-30, management targeting roughly 37 by 2026-12-31 — so revenue compounds off site activations and per-site utilization rather than a pipeline event.\n\nWhat has changed since the last note: price kept the gain without new information. The 2026-08-21 close of $17.14 sits 1.3% below the 52-week high of $17.36, above the $16.73 close of 2026-08-14, on a three-month price change of +55.5%. RSI(14) eased to 74.1 from 77.2 over the same week. The last dated company item is the Canaccord Genuity 46th Annual Growth Conference appearance on 2026-08-11; the last fresh sell-side action was 2026-08-07. Roughly two months separate the tape from its next scheduled checkpoint.\n\n## Bull Case\n- Q2 2026 (2026-08-06): revenue $29.133M vs $26.259M consensus and $24.2M in Q2 2025; HEPZATO KIT $27.1M vs $22.5M, CHEMOSAT $2.0M vs $1.7M.\n- Gross margin 90% in Q2 2026 vs 86% in Q2 2025; approximately 30% HEPZATO volume growth year over year, against an FY guide that embeds at least 28% (2026-08-06 release).\n- Balance sheet at 2026-06-30: cash and investments $95.9M, no debt; operations provided $5.7M of cash in the quarter. Two Phase 2 programs are funded from that base per the same release.\n- Checkable distribution math: two centers added in Q2 to reach 31, roughly six more planned to reach ~37 by 2026-12-31.\n- Post-print sell-side action inside 24 hours: BTIG to $21 on 2026-08-06, HC Wainwright to $32 on 2026-08-07, both Buy-rated. The 2026-08-21 close of $17.14 is under both published marks.\n- Insider record runs the other way from a distribution pattern: the most recent open-market Form 4 transactions on file are purchases — with no open-market insider sales recorded for July or August 2026 in public Form 4 aggregation as of 2026-08-23.\n- Far larger liver-dominant populations sit behind the label: Phase 2 in third-line liver-dominant metastatic colorectal cancer (first patient dosed 2025-08-19 at City of Hope; ~90 patients, more than 20 US and EU sites), plus an initiated Phase 2 in HER2-negative metastatic breast cancer. Company-stated US addressable population for 3L liver-dominant mCRC is 6,000–10,000 patients per year.\n\n## Bear Case\n- The raise was thin relative to the prior mark: $104–108M against $103.242M consensus. The surprise was concentrated in the reported quarter.\n- Net income was $2.7M in Q2 2026 and $2.7M in Q2 2025 on roughly 20% revenue growth, and operating cash flow fell to $5.7M from $7.3M. Incremental gross profit is being absorbed by trial spend.\n- Label expansion resolves nothing before the end of the decade: mCRC Phase 2 hepatic-PFS anticipated mid-2028, overall survival late-2028.\n- Concentration: HEPZATO was $27.1M of $29.133M of Q2 revenue. A single payer decision, REMS change or safety disclosure reaches nearly the whole P&L.\n- Coverage is thin and dispersed. Two published post-print targets, $21 and $32, both Buy — a spread that reflects unsettled per-center productivity assumptions rather than a settled valuation.\n- Empty calendar. Two and a half weeks after the print there is still no company-confirmed event inside 30 days, so the marginal bid has to come from flow while price sits 1.3% under the 52-week high with RSI(14) at 74.1.\n- Publicly aggregated short interest sits near 2.69M shares, about 7.80% of shares outstanding, on data updated 2026-08-04; a second aggregator shows 2.184M shares, 6.38% of float. Neither figure is large enough to make squeeze mechanics the driver, and the discrepancy between the two is itself a caution on precision.\n\n## Setup & Price Structure\n- Reference session 2026-08-21: close $17.14, 52-week high $17.36 (-1.3% below), a three-month price change of +55.5%, RSI(14) 74.1.\n- One-week change in the momentum profile: price rose from the $16.73 close of 2026-08-14 while RSI(14) fell from 77.2 to 74.1. That is a single weekly observation and supports no conclusion about exhaustion on its own; it is recorded here so the next reading can be compared against it.\n- The narrative is **maturing**. The narrative is known and still working, but new attention has stopped arriving — fresh headlines end at the 2026-08-07 target raise and the 2026-08-11 conference slot, price is grinding rather than gapping, and no new sell-side initiation has appeared since. It was accelerating through the 2026-08-06 print week; the advance since has come without incremental news.\n- Crowding observables, stated as observables: RSI(14) above 70 at both the 2026-08-14 and 2026-08-21 closes; price within 1.3% of the 52-week high; no insider open-market sales on the Form 4 record for July–August 2026; no shelf takedown, ATM draw or registered offering disclosed since the 2026-08-06 8-K; No moving-average distance is asserted here because none was verified for this refresh.\n- The structural level: a weekly close below $14.00 gives back the entire post-print advance, roughly 18% under the 2026-08-21 close. The upside structural question is whether $17.36 clears on a closing weekly reading; repeated failure there, with the calendar empty, is what a stall looks like on the tape.\n\n## Catalyst Calendar (next 30 days)\n- Through ~2026-09-22: no company-confirmed event located as of 2026-08-23. The 2026-08-11 Canaccord Genuity 46th Annual Growth Conference appearance has elapsed. Any September investor-conference slot would be announced by press release; none was found.\n- 2026-10-23 to 2026-10-27 — ESMO Congress 2026, IFEMA Madrid. Investigator-sponsored percutaneous hepatic perfusion data has surfaced at ESMO meetings before; the 2026-08-06 release cited a 60% hepatic partial response rate in heavily pretreated liver-dominant metastatic breast cancer presented at ESMO Breast Cancer 2026.\n- ~2026-11-05 (est.) — Q3 2026 results. First verifiable read on the $104–108M FY guide, the 86–89% gross-margin band, and center activations toward ~37.\n- 2026-12-31 — management's stated year-end target of roughly 37 active centers.\n\n## What Would Change Our Mind\nThe advance off 2026-08-06 is the entire near-term expression of this thesis, and it now has to survive two months without a dated event. Losing the pre-print shelf ends it: a weekly close below $14.00 retraces the full move and would place the tape back where it stood before the beat. Short of that, the fundamental conditions that would break the frame are specific — FY26 revenue guided beneath the $104M floor at the Q3 print, an active-center count materially short of ~37 by the 2026-12-31 target, a third consecutive quarter of flat net income against double-digit revenue growth, or a shelf takedown or ATM usage disclosed despite $95.9M of cash and no debt at 2026-06-30. A narrative-side break would be ESMO 2026 passing 2026-10-27 with no new HEPZATO or CHEMOSAT abstract, leaving nothing clinical between now and the mid-2028 hepatic-PFS readout. If the theme flips to saturated — mainstream coverage arriving after the move, no new bid — the same $14.00 weekly condition is what grades it.\n\n## Correlation Notes\n- Revenue is US procedure reimbursement, so the sensitivity is to CMS and commercial payer policy and to hospital capital/staffing cycles, not to the rate path or AI capex. This is an inference from the revenue mix disclosed 2026-08-06, not a measured beta.\n- Trades with small-cap biotech risk appetite more than with the broad index; with two published post-print targets and no consensus depth behind them, news gaps in this name tend to be wider than the sector's.\n- CHEMOSAT at $2.0M of Q2 revenue leaves European FX exposure immaterial to the P&L at current scale.\n- The nearest read-across is other single-product commercial-stage oncology device names on center-activation ramps; the shared risk is a payer or REMS event, which hits utilization at every active site at once.",
  "first_seen": "2026-08-12",
  "last_analyzed": "2026-08-23T12:45:27+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}